MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ
0.6880
-0.0320
-4.44%
Opening 11:02 08/12 EDT
OPEN
0.7223
PREV CLOSE
0.7200
HIGH
0.7400
LOW
0.6840
VOLUME
137.62K
TURNOVER
--
52 WEEK HIGH
2.190
52 WEEK LOW
0.4687
MARKET CAP
18.89M
P/E (TTM)
-0.2654
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
Dow Jones · 4h ago
*Citius Oncology Expands Board With Appointment of Independent Director Jonathan Peri
Dow Jones · 4h ago
Weekly Report: what happened at CTXR last week (0803-0807)?
Weekly Report · 2d ago
Citius Oncology Reports 78% QoQ Growth In New Institutional Accounts Ordering LYMPHIR; Near‑Universal Payer Coverage Expands Market Access With Initial CTCL Market Exceeding $400M
Benzinga · 08/05 13:22
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
PR Newswire · 08/05 13:17
Weekly Report: what happened at CTXR last week (0727-0731)?
Weekly Report · 08/03 09:43
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 07/29 21:06
Weekly Report: what happened at CTXR last week (0720-0724)?
Weekly Report · 07/27 09:46
More
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Webull offers Citius Pharmaceuticals Inc stock information, including NASDAQ: CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.